NOXXON Pharma Raises Additional €2M in Series D Financing

NOXXON Pharma AG, a Berlin, Germany-based biotechnology company developing a promising new class of therapeutics called Spiegelmers, which are oligonucleotides made from the L-stereoisomer of RNA, has completed an additional €2m funding in its series D round.

This adds to the €33m raised in May 2010, and brings the total amount in this series D financing to €35m in aggregate.